21Shares Moves Forward with Injective ETF
Crypto investment firm 21Shares has officially filed with the U.S. Securities and Exchange Commission (SEC) for a spot ETF targeting Injective (INJ). The filing represents a key step in expanding institutional access to DeFi-focused digital assets.
The proposed ETF will hold physical INJ tokens in cold storage, mirroring the structure of approved spot ETFs for Bitcoin and Ethereum. According to 21Shares’ official filing, the fund is designed to give investors direct exposure to Injective, simplifying participation in the blockchain’s growing ecosystem.
The news was shared via Injective’s official X account, boosting token visibility and reinforcing market sentiment. Observers note that the ETF follows a similar filing by Canary Capital in July, marking a broader institutional push into Injective and Layer-1 blockchain infrastructure.
Injective’s Growing Market Position
Injective is a high-performance Layer 1 blockchain optimised for decentralised finance (DeFi). The network supports over 25,000 TPS using a Delegated Proof-of-Stake (DPoS) consensus mechanism. This allows for low-latency trading, high scalability, and efficient transaction finality. It also makes it suitable for both DeFi applications and real-world asset integration.
The network’s architecture integrates exchange primitives such as CosmWasm-based composability and Comet BFT consensus. It addresses common DeFi challenges like fragmented liquidity and slow transaction processing.
Key developments on Injective include:
- Native Ethereum Virtual Machine (EVM) support for cross-chain compatibility
- Pre-IPO market infrastructure for institutional participants
- Formation of the Injective Council, guiding governance and strategic objectives
- Collaborations with Google Cloud, T-Mobile, Deutsche Telekom, YZi Labs, Galaxy Digital, and BitGo
These initiatives reflect the platform’s ambition to strengthen its position among top blockchain networks while attracting institutional adoption.
ETF Filing Boosts Institutional Access
The 21Shares Injective ETF is part of a growing trend of regulated crypto investment vehicles. By holding physical INJ in cold storage, the ETF provides secure and direct exposure to the blockchain’s token while mitigating risks associated with self-custody.
Industry participants view the filing as a step toward mainstream DeFi integration, giving institutional investors a regulated path to participate in innovative digital assets.
More News: NewLimit Raises $45 Million to Advance Longevity Research
INJ Price Holds Amid ETF News
Following the filing, INJ traded near $8.75, showing resilience despite broader crypto market volatility. The token had dipped to $7.80 on October 17, 2025, but bullish interest, supported by ETF news, helped it recover above $8.
INJ remains down from previous highs, including $52.75 in March 2024 and $35 in December 2024. Market watchers are observing key support levels near $8.00, with ETF-related optimism potentially driving accumulation..
Investments in treasury assets, such as Pineapple Financial’s $100 million allocation and INJ, reinforce bullish sentiment. While the ETF filing hasn’t triggered a major rally, institutional confidence provide long-term support for the token.
Injective’s Institutional and DeFi Appeal
Injective is widely recognised for its robust infrastructure and focus on both institutional and DeFi markets. Its high throughput, low latency, and MEV-resistant trading make it attractive for professional trading.
The upcoming ETF could enhance liquidity, attract new investors, and increase adoption across multiple sectors. By providing a regulated vehicle, 21Shares bridges the gap between traditional finance and emerging DeFi ecosystems.
Outlook for the 21Shares Injective ETF
With the SEC review process underway, industry observers anticipate that the ETF will broaden investor access to Injective while supporting token adoption. The filing highlights rising institutional interest in DeFi Layer-1 solutions and underscores 21Shares’ commitment to expanding regulated crypto offerings.
As adoption grows, the ETF could also positively influence INJ token liquidity, giving professional and retail investors alike a clear, regulated entry point. Combined with Injective’s technical advantages, partnerships, and governance initiatives, the ETF positions the network for sustained growth.
To stay updated on crypto venture capital funding and market trends, visit our venture capital news section for more insights.